What is your baseline protocol for total-body skin exams in patients with systemic sclerosis on immunosuppression: routine annual/biannual screening or interval follow-up tailored strictly to personal skin cancer history?

I don't know of much evidence around this but it does seem clear that attempting to stratify risk based solely on immunomodulatory medication doesn't make good clinical sense; it does seem that the patient's baseline risk is still highly relevant and likely the primary driver of overall risk. In mos...